

January 11, 2021



# DiaMedica Therapeutics to Present at the H.C. Wainwright BioConnect Conference

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being held virtually between January 11-14, 2021.

The recorded presentation will be available on the Investors section of the Company's website at <https://ir.diamedica.com/events-and-presentations> beginning Monday, January 11<sup>th</sup>.

## ***About DiaMedica Therapeutics Inc.***

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. DiaMedica's shares are listed on The Nasdaq Capital Market under the trading symbol "DMAC."

For more information, please visit [www.diamedica.com](http://www.diamedica.com).

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20210111005244/en/>

Scott Kellen  
Chief Financial Officer  
Phone: (763) 496-5118  
[skellen@diamedica.com](mailto:skellen@diamedica.com)

Source: DiaMedica Therapeutics Inc.